PRINCETON, N.J.--(BUSINESS WIRE)-- Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has completed enrollment of the first 40 subject cohort in the dose-ranging Phase II study of ADXS-HPV, an immunotherapy for Cervical Intraepithelial Neoplasia (CIN).
The ADXS-HPV CIN study is a randomized, single blind, placebo controlled Phase II dose-ranging study designed to assess the safety and efficacy in up to 3 different dose cohorts.
“We are pleased to complete enrollment in this cohort and take the next step towards completing the CIN study,” commented Advaxis Chairman / CEO Thomas A. Moore. “The six-month follow-up evaluation for this cohort will be completed by this January. The mid-dose leg will begin recruitment immediately. Our plan is to release the low dose results in early 2012.”
About Cervical Intraepithelial Neoplasia (CIN)
CIN is caused by the human papilloma virus and is diagnosed in approximately 500,000 women annually in the US. If left untreated, CIN2/3 is likely to progress to invasive cervical cancer. There is currently no alternative to surgery. Today, there are approximately 250,000 surgical procedures conducted annually to treat CIN 2/3.
About Advaxis, Inc.
Advaxis is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Our novel platform technology generates a more comprehensive immune response by serving as its own adjuvant, directing antigen presentation, increasing tumor infiltrating killer T-cells, and decreasing Tregs/MDSCs in the tumor. Today, the Company has over fifteen (15) distinct constructs in various stages of development, directly developed by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, and the Department of Homeland Security among others. Additional information can be found at: advaxis.com | facebook | twitter | LinkedIn
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
CONTACT:
Advaxis Incorporated
Conrad Mir, 609-452-9813
Executive Director
609-452-9818 (FAX)
[email protected]
or
Diana Moore, 609-452-9813
Analyst
[email protected]
KEYWORDS: United States North America New Jersey
INDUSTRY KEYWORDS: Women Health Biotechnology Clinical Trials Infectious Diseases Oncology Research Consumer Science
MEDIA:
| Logo |